Search

Aurinia Pharmaceuticals Inc

Închisă

SectorSănătate

16.73 0.97

Rezumat

Modificarea prețului

24h

Curent

Minim

16.48

Maxim

16.8

Indicatori cheie

By Trading Economics

Venit

3.1M

37M

Vânzări

5.5M

83M

P/E

Medie Sector

7.3

57.366

EPS

0.28

Marjă de profit

44.958

Angajați

128

EBITDA

4.8M

55M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+8.63% upside

Dividende

By Acuity

Următoarele câștiguri

3 nov. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

331M

2.2B

Deschiderea anterioară

15.76

Închiderea anterioară

16.73

Sentimentul știrilor

By Acuity

21%

79%

58 / 340 Clasament în Healthcare

Aurinia Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

25 aug. 2026, 19:36 UTC

Aurinia Pharmaceuticals Inc is trading higher amid a positive market environment, despite pulling back from earlier session highs. No specific news was identified.

24 aug. 2026, 22:01 UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, continuing a trend of declines observed over the past three sessions. No specific news was identified.

21 aug. 2026, 23:06 UTC

Aurinia Pharmaceuticals Inc. shares are higher in after-market hours, reflecting routine trading activity and maintaining a position above the 20-day moving average.

20 aug. 2026, 21:46 UTC

Aurinia Pharmaceuticals Inc shares are trading lower in after-market hours. No specific news was identified to explain the decline.

19 aug. 2026, 23:02 UTC

News

Aurinia Pharmaceuticals settled patent litigation with Teva, securing exclusivity for voclosporin until December 2036. Shares rose in after-hours trading following the announcement.

18 aug. 2026, 19:56 UTC

Aurinia Pharmaceuticals Inc is trading higher today, though no specific news has been identified. Rising Treasury yields may pose challenges for equities.

17 aug. 2026, 20:02 UTC

Social Media

Aurinia Pharmaceuticals shares are lower amid broader market declines and rising crude oil prices, despite some social media chatter about potential buyout interest.

14 aug. 2026, 19:26 UTC

Aurinia Pharmaceuticals shares are higher today, rebounding after earlier volatility amid broader market concerns over disappointing U.S. retail sales figures.

13 aug. 2026, 19:56 UTC

News

Aurinia Pharmaceuticals shares are lower today, despite ongoing sales growth of Lupkynis and a recent acquisition of Kezar Life Sciences.

11 aug. 2026, 20:06 UTC

Aurinia Pharmaceuticals Inc shares are trading lower today, continuing a trend of three consecutive daily declines amid no specific news to explain the movement.

10 aug. 2026, 20:06 UTC

News

Aurinia Pharmaceuticals shares decline following multiple downgrades from research firms, despite Royal Bank of Canada raising its price target to $16.00.

7 aug. 2026, 19:16 UTC

News

Aurinia Pharmaceuticals shares are lower today, despite earlier gains. RBC Capital raised the price target to $16.00 from $15.00, maintaining a Sector Perform rating.

6 aug. 2026, 20:02 UTC

Event
News

Aurinia Pharmaceuticals reported second-quarter EPS of $0.28, exceeding estimates. The stock is higher today amid strong financial results and reaffirmed revenue guidance for 2026.

4 aug. 2026, 19:46 UTC

Aurinia Pharmaceuticals Inc is trading higher amid a positive market environment and a decline in crude oil prices, which may benefit consumer spending.

3 aug. 2026, 22:01 UTC

Aurinia Pharmaceuticals shares are higher in after-market hours, despite being below the 20-day moving average and three prior lower daily closes.

1 aug. 2026, 00:01 UTC

Aurinia Pharmaceuticals Inc is trading lower in after-market hours, reflecting a significant decline in the overall market and ongoing weakness in performance metrics.

31 iul. 2026, 21:01 UTC

Aurinia Pharmaceuticals Inc is higher in after-market trading, rising notably from a flat start. The stock remains below its 20-day moving average.

30 iul. 2026, 20:31 UTC

Aurinia Pharmaceuticals Inc. shares rose in after-market trading, following a broader market trend as the S&P 500 also gained. No specific news was identified.

29 iul. 2026, 22:01 UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, showing notable weakness and trading below its 20-day moving average. No specific news was identified.

28 iul. 2026, 19:36 UTC

Aurinia Pharmaceuticals shares are lower, reflecting volatility amid broader market conditions. The stock is trading significantly below its 20-day moving average.

27 iul. 2026, 19:16 UTC

Aurinia Pharmaceuticals is trading higher, benefiting from lower oil prices and easing inflation concerns ahead of the Federal Reserve meeting later this week.

24 iul. 2026, 18:26 UTC

Aurinia Pharmaceuticals is trading higher, despite pulling back from earlier gains. Broader market volatility, influenced by declining oil prices, impacts sentiment.

22 iul. 2026, 19:46 UTC

Aurinia Pharmaceuticals shares are lower today, continuing a decline since Tuesday's close. The stock is near its one-month trading range's lower end.

21 iul. 2026, 19:16 UTC

Aurinia Pharmaceuticals is higher today, supported by a broader market uptick as investor interest in AI-related stocks grows ahead of major tech earnings.

20 iul. 2026, 20:01 UTC

Aurinia Pharmaceuticals is lower today, reflecting broader market declines amid geopolitical tensions and oil price fluctuations. The stock hit a session low earlier.

Comparație

Modificare preț

Aurinia Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

8.63% sus

Prognoză pe 12 luni

Medie 18 USD  8.63%

Maxim 21 USD

Minim 16 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAurinia Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

3 ratings

2

Cumpărare

1

Păstrare

0

Vânzare

Sentiment

By Acuity

58 / 340 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
help-icon Live chat